• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

PwC: Pharma & Biotech Dealmaking Heats Up Despite Uncertainties

by Fred Pennic 06/21/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
PwC: Pharma & Biotech Dealmaking Heats Up Despite Uncertainties

What You Should Know: 

– The pharmaceutical and life sciences (PLS) sector is experiencing a resurgence in dealmaking activity, with a 20% increase in deal volume over the past year reported, according to PwC’s latest US Midyear Deals 2024 Outlook for Pharmaceutical and Life Sciences. 

– M&A activity in the PLS sector is expected to remain strong throughout 2024 and potentially into 2025. Clarity on factors like US election outcomes and Federal Reserve interest rate decisions could further bolster investor confidence and fuel even more deals.

Key Drivers of Increased M&A Activity:

  • Innovation Focus: Companies are strategically acquiring assets in high-innovation areas like gene therapy and novel drug treatments to address patent expirations later this decade.
  • Strong IPO Market: The reopening of the IPO market indicates renewed investor confidence, potentially fueling further M&A activity.
  • Portfolio Restructuring: Companies are divesting non-core assets and reorienting their focus areas to maximize growth, especially with rising financing costs.
  • Strong Product Pipelines: A surge in successful drug approvals and advancements in therapeutic areas like NASH treatments are attracting acquirers.

Challenges and Considerations for PLS M&A:

  • Regulatory Scrutiny: Increased scrutiny from the Department of Justice and FTC may impact deal strategies due to concerns about competition and patient access to medication. Companies will need to ensure deals meet stricter standards regarding market share and potential monopolies.
  • Planning for Uncertainty: Navigating a dynamic environment requires scenario planning and flexibility to maximize value creation in M&A pursuits.
  • Talent Retention: Retaining key talent is crucial during extended deal periods to ensure successful integration and future growth.

The GLP-1 Effect:

The ongoing impact of glucagon-like peptide-1 (GLP-1) drugs across various therapeutic areas is being closely monitored by dealmakers. Understanding the long-term effects of these drugs will be essential for future deal assessments.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Redesign Health Study: 71% of Health Systems Adopt an "Epic-First" AI Purchasing Strategy

Redesign Health Study: 71% of Health Systems Adopt an “Epic-First” AI Purchasing Strategy

iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform

M&A: iRhythm to Acquire VitalConnect for $287.5M to Build Broad Cardiac Intelligence Platform

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |